Metformina + Vildagliptina Aurovitas

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Aurovitas, is a biguanide presented as an oral tablet for oral use. It, together with vildagliptin, is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformina + Vildagliptina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality, regulatory compliance and reliable logistics across EU and global markets through validated manufacturing processes and continuous quality monitoring.

Metformina + Vildagliptina combines metformin, a biguanide, with vildagliptin, a DPP‑4 inhibitor, to improve glycemic control in type 2 diabetes.

Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when used with diet and exercise. Adjunct therapy: provides additional glucose‑lowering effect when metformin alone is insufficient. Combination therapy: allows simultaneous targeting of hepatic glucose production and incretin‑mediated insulin secretion.

Metformina + Vildagliptina is associated with several adverse reactions that vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Hypoglycemia: especially when combined with insulin or sulfonylureas. - Upper respiratory tract infection: mild symptoms. - Dizziness: transient episodes.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycemia: prolonged low blood glucose requiring medical intervention. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatic failure. - Allergic reactions: rash, pruritus, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible patients.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal function: assess baseline creatinine clearance and adjust therapy as needed. Hepatic function: monitor liver enzymes because metformin‑associated lactic acidosis risk increases with hepatic impairment. Cardiovascular status: avoid in patients with unstable heart failure or severe hypoxia. Concomitant hypoglycemics: adjust doses of insulin or sulfonylureas to reduce hypoglycemia risk. Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. Store at ambient temperature: keep below 25 °C, in the original packaging, and protect from moisture.

Metformina + Vildagliptina may interact with several medicines, requiring caution or avoidance.

Major Interactions (Avoid): - Sulfonylureas or insulin: increased risk of severe hypoglycemia. - Iodinated contrast agents: potential for metformin‑associated lactic acidosis. - Cimetidine: may raise metformin plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate vildagliptin exposure. - Excessive alcohol: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Beta‑blockers: can mask hypoglycemia symptoms. - Thyroid hormones: may alter glucose metabolism. - Rifampin: may reduce vildagliptin plasma levels, decreasing efficacy.